Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 54 | 2020 | 466 | 7.520 |
Why?
|
Substance-Related Disorders | 26 | 2019 | 94 | 7.020 |
Why?
|
HIV Seropositivity | 24 | 2019 | 49 | 3.890 |
Why?
|
Neuropsychological Tests | 66 | 2019 | 1196 | 3.540 |
Why?
|
AIDS Dementia Complex | 15 | 2018 | 39 | 2.060 |
Why?
|
Cognition Disorders | 18 | 2018 | 985 | 1.890 |
Why?
|
Psychomotor Performance | 18 | 2018 | 205 | 1.730 |
Why?
|
Memory Disorders | 9 | 2017 | 159 | 1.690 |
Why?
|
Adult | 88 | 2019 | 7831 | 1.590 |
Why?
|
Decision Making | 9 | 2016 | 223 | 1.570 |
Why?
|
Cognition | 22 | 2019 | 1339 | 1.490 |
Why?
|
Middle Aged | 77 | 2020 | 8923 | 1.430 |
Why?
|
Sex Characteristics | 5 | 2018 | 116 | 1.410 |
Why?
|
Acquired Immunodeficiency Syndrome | 8 | 2017 | 41 | 1.370 |
Why?
|
Memory, Short-Term | 12 | 2019 | 97 | 1.320 |
Why?
|
Hepatitis C | 5 | 2015 | 32 | 1.290 |
Why?
|
Male | 86 | 2020 | 14772 | 1.230 |
Why?
|
Impulsive Behavior | 6 | 2013 | 15 | 1.190 |
Why?
|
Humans | 110 | 2020 | 27072 | 1.070 |
Why?
|
Anti-HIV Agents | 10 | 2019 | 64 | 1.050 |
Why?
|
Reaction Time | 15 | 2018 | 102 | 1.030 |
Why?
|
Learning | 3 | 2013 | 71 | 1.020 |
Why?
|
Attention | 11 | 2019 | 124 | 0.980 |
Why?
|
Female | 64 | 2019 | 15212 | 0.960 |
Why?
|
Drug Users | 3 | 2015 | 3 | 0.950 |
Why?
|
HIV-1 | 15 | 2017 | 221 | 0.940 |
Why?
|
Risk-Taking | 4 | 2016 | 34 | 0.900 |
Why?
|
Cocaine-Related Disorders | 4 | 2017 | 13 | 0.880 |
Why?
|
Cognitive Dysfunction | 9 | 2020 | 1061 | 0.870 |
Why?
|
Antiretroviral Therapy, Highly Active | 10 | 2017 | 61 | 0.860 |
Why?
|
Neurocognitive Disorders | 3 | 2019 | 12 | 0.820 |
Why?
|
Gambling | 6 | 2013 | 8 | 0.720 |
Why?
|
Diagnostic Tests, Routine | 1 | 2019 | 12 | 0.660 |
Why?
|
Memory, Episodic | 2 | 2017 | 116 | 0.650 |
Why?
|
HIV Seronegativity | 6 | 2016 | 18 | 0.570 |
Why?
|
Spatial Learning | 1 | 2017 | 4 | 0.570 |
Why?
|
Spatial Navigation | 1 | 2017 | 4 | 0.570 |
Why?
|
Mumps | 1 | 2017 | 1 | 0.570 |
Why?
|
Mumps Vaccine | 1 | 2017 | 1 | 0.570 |
Why?
|
Immunization Programs | 1 | 2017 | 2 | 0.570 |
Why?
|
Epidemiological Monitoring | 1 | 2017 | 15 | 0.560 |
Why?
|
Homosexuality, Male | 5 | 2017 | 28 | 0.540 |
Why?
|
Mental Recall | 3 | 2016 | 62 | 0.530 |
Why?
|
Executive Function | 9 | 2019 | 111 | 0.530 |
Why?
|
Memory | 7 | 2019 | 297 | 0.520 |
Why?
|
Marijuana Abuse | 3 | 2014 | 6 | 0.500 |
Why?
|
Depression | 7 | 2019 | 444 | 0.490 |
Why?
|
Brain | 10 | 2020 | 1649 | 0.470 |
Why?
|
Delay Discounting | 1 | 2015 | 24 | 0.470 |
Why?
|
Stress Disorders, Post-Traumatic | 3 | 2015 | 231 | 0.470 |
Why?
|
Hospitalization | 1 | 2017 | 300 | 0.470 |
Why?
|
Verbal Learning | 6 | 2015 | 33 | 0.460 |
Why?
|
Heroin Dependence | 5 | 2013 | 9 | 0.450 |
Why?
|
Schizophrenic Psychology | 4 | 2002 | 14 | 0.450 |
Why?
|
Cohort Studies | 18 | 2020 | 1890 | 0.440 |
Why?
|
Antisocial Personality Disorder | 3 | 2010 | 8 | 0.430 |
Why?
|
Sex Factors | 6 | 2019 | 464 | 0.430 |
Why?
|
Adolescent | 12 | 2017 | 2172 | 0.410 |
Why?
|
Severity of Illness Index | 6 | 2019 | 879 | 0.410 |
Why?
|
Suicide, Attempted | 1 | 2012 | 14 | 0.390 |
Why?
|
Amphetamine-Related Disorders | 2 | 2013 | 5 | 0.380 |
Why?
|
Young Adult | 10 | 2019 | 1994 | 0.380 |
Why?
|
Analysis of Variance | 6 | 2011 | 260 | 0.370 |
Why?
|
Serial Learning | 1 | 2011 | 7 | 0.370 |
Why?
|
Unsafe Sex | 1 | 2010 | 2 | 0.350 |
Why?
|
Affective Symptoms | 1 | 2010 | 11 | 0.340 |
Why?
|
Motor Skills | 1 | 2010 | 48 | 0.340 |
Why?
|
Age Factors | 9 | 2019 | 766 | 0.340 |
Why?
|
Case-Control Studies | 9 | 2019 | 587 | 0.320 |
Why?
|
Central Nervous System Diseases | 1 | 2009 | 17 | 0.310 |
Why?
|
Alcoholism | 3 | 2014 | 67 | 0.310 |
Why?
|
Neuropsychology | 1 | 2008 | 3 | 0.310 |
Why?
|
Auditory Perception | 3 | 2006 | 34 | 0.300 |
Why?
|
Women | 1 | 2008 | 14 | 0.300 |
Why?
|
Career Choice | 1 | 2008 | 25 | 0.300 |
Why?
|
Professional Role | 1 | 2008 | 31 | 0.300 |
Why?
|
Diabetes Complications | 2 | 2018 | 56 | 0.300 |
Why?
|
Marijuana Smoking | 2 | 2019 | 2 | 0.290 |
Why?
|
Choice Behavior | 4 | 2013 | 46 | 0.290 |
Why?
|
Predictive Value of Tests | 5 | 2013 | 474 | 0.290 |
Why?
|
Comorbidity | 4 | 2015 | 481 | 0.280 |
Why?
|
Practice Patterns, Physicians' | 1 | 2008 | 111 | 0.280 |
Why?
|
Substance Abuse, Intravenous | 2 | 2005 | 10 | 0.280 |
Why?
|
Schizophrenia | 3 | 2002 | 62 | 0.280 |
Why?
|
Prefrontal Cortex | 4 | 2014 | 136 | 0.270 |
Why?
|
Methamphetamine | 1 | 2007 | 22 | 0.270 |
Why?
|
Magnetic Resonance Imaging | 9 | 2020 | 1112 | 0.260 |
Why?
|
Aged | 17 | 2019 | 8997 | 0.250 |
Why?
|
Risk Factors | 12 | 2018 | 2302 | 0.250 |
Why?
|
Depressive Disorder | 3 | 2014 | 177 | 0.240 |
Why?
|
Psychometrics | 4 | 2013 | 220 | 0.240 |
Why?
|
Exploratory Behavior | 1 | 2005 | 10 | 0.240 |
Why?
|
Statistics as Topic | 3 | 2013 | 105 | 0.240 |
Why?
|
Cross-Sectional Studies | 5 | 2019 | 891 | 0.240 |
Why?
|
Problem Solving | 2 | 2002 | 40 | 0.240 |
Why?
|
Sexual Behavior | 1 | 2005 | 54 | 0.230 |
Why?
|
Psychiatric Status Rating Scales | 8 | 2008 | 310 | 0.220 |
Why?
|
Stress, Psychological | 2 | 2017 | 235 | 0.220 |
Why?
|
Longitudinal Studies | 9 | 2018 | 1368 | 0.220 |
Why?
|
Visual Perception | 2 | 2016 | 30 | 0.210 |
Why?
|
Individuality | 2 | 2018 | 23 | 0.210 |
Why?
|
Concept Formation | 1 | 2002 | 8 | 0.200 |
Why?
|
Social Adjustment | 1 | 2002 | 23 | 0.200 |
Why?
|
Prospective Studies | 11 | 2018 | 1778 | 0.200 |
Why?
|
Psychotic Disorders | 1 | 2002 | 39 | 0.200 |
Why?
|
Personality | 2 | 2013 | 53 | 0.190 |
Why?
|
Self Report | 3 | 2018 | 223 | 0.190 |
Why?
|
Intelligence Tests | 2 | 2011 | 16 | 0.180 |
Why?
|
Cues | 2 | 2000 | 38 | 0.180 |
Why?
|
Educational Status | 5 | 2015 | 293 | 0.180 |
Why?
|
Central Nervous System Stimulants | 3 | 2017 | 41 | 0.170 |
Why?
|
Bipolar Disorder | 2 | 2002 | 130 | 0.170 |
Why?
|
Thinking | 1 | 2000 | 14 | 0.170 |
Why?
|
Statistics, Nonparametric | 2 | 2016 | 125 | 0.160 |
Why?
|
White Matter | 2 | 2018 | 134 | 0.160 |
Why?
|
Benzoxazines | 1 | 2019 | 3 | 0.160 |
Why?
|
Drug Substitution | 1 | 2019 | 4 | 0.160 |
Why?
|
Obesity, Abdominal | 1 | 2019 | 19 | 0.160 |
Why?
|
Disease Progression | 3 | 2015 | 673 | 0.150 |
Why?
|
Demography | 3 | 2014 | 72 | 0.150 |
Why?
|
Incidence | 2 | 2018 | 759 | 0.150 |
Why?
|
Energy Metabolism | 1 | 2018 | 54 | 0.150 |
Why?
|
Vaccination Coverage | 1 | 2017 | 1 | 0.140 |
Why?
|
Spain | 1 | 2017 | 8 | 0.140 |
Why?
|
United States | 8 | 2019 | 2035 | 0.140 |
Why?
|
Chicago | 3 | 2013 | 949 | 0.140 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 2 | 2010 | 39 | 0.140 |
Why?
|
Crack Cocaine | 2 | 2014 | 2 | 0.140 |
Why?
|
Marijuana Use | 1 | 2017 | 1 | 0.140 |
Why?
|
Psychological Tests | 3 | 2007 | 52 | 0.140 |
Why?
|
Vaccination | 1 | 2017 | 33 | 0.140 |
Why?
|
Host-Pathogen Interactions | 1 | 2017 | 13 | 0.140 |
Why?
|
Disease Outbreaks | 1 | 2017 | 80 | 0.140 |
Why?
|
Personality Tests | 1 | 2016 | 5 | 0.140 |
Why?
|
Leukocytes, Mononuclear | 1 | 2017 | 53 | 0.140 |
Why?
|
Aged, 80 and over | 8 | 2019 | 4777 | 0.130 |
Why?
|
Sexual and Gender Minorities | 1 | 2017 | 27 | 0.130 |
Why?
|
Antirheumatic Agents | 1 | 2017 | 85 | 0.130 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2014 | 278 | 0.130 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 139 | 0.130 |
Why?
|
Obesity | 2 | 2019 | 311 | 0.130 |
Why?
|
Aging | 3 | 2017 | 1544 | 0.130 |
Why?
|
Time Factors | 4 | 2013 | 1433 | 0.130 |
Why?
|
Cerebral Cortex | 2 | 2016 | 155 | 0.130 |
Why?
|
Personality Inventory | 1 | 2016 | 73 | 0.130 |
Why?
|
Smoking | 1 | 2017 | 176 | 0.130 |
Why?
|
Infant | 1 | 2017 | 564 | 0.120 |
Why?
|
Hippocampus | 1 | 2017 | 273 | 0.120 |
Why?
|
Child, Preschool | 1 | 2017 | 641 | 0.120 |
Why?
|
Adiponectin | 1 | 2015 | 10 | 0.120 |
Why?
|
RNA, Viral | 1 | 2015 | 45 | 0.120 |
Why?
|
Chi-Square Distribution | 3 | 2014 | 139 | 0.120 |
Why?
|
Catechol O-Methyltransferase | 1 | 2014 | 1 | 0.120 |
Why?
|
Interleukin-6 | 1 | 2015 | 74 | 0.120 |
Why?
|
CD4 Lymphocyte Count | 4 | 2017 | 53 | 0.120 |
Why?
|
Prevalence | 4 | 2017 | 443 | 0.110 |
Why?
|
Gyrus Cinguli | 1 | 2014 | 14 | 0.110 |
Why?
|
Quality of Life | 1 | 2019 | 629 | 0.110 |
Why?
|
Drug Therapy, Combination | 3 | 2017 | 161 | 0.110 |
Why?
|
Menopause | 1 | 2014 | 101 | 0.110 |
Why?
|
Zidovudine | 3 | 1999 | 13 | 0.100 |
Why?
|
Child | 1 | 2017 | 1295 | 0.100 |
Why?
|
Genotype | 4 | 2014 | 346 | 0.100 |
Why?
|
Patient Selection | 1 | 2014 | 194 | 0.100 |
Why?
|
Anxiety | 2 | 2010 | 156 | 0.100 |
Why?
|
Apolipoprotein E4 | 1 | 2014 | 263 | 0.100 |
Why?
|
Viral Load | 3 | 2017 | 69 | 0.100 |
Why?
|
Follow-Up Studies | 6 | 2015 | 1792 | 0.100 |
Why?
|
Association Learning | 1 | 2012 | 2 | 0.100 |
Why?
|
Hospitals, Veterans | 1 | 2012 | 6 | 0.100 |
Why?
|
Regression Analysis | 4 | 2016 | 260 | 0.100 |
Why?
|
Orientation | 1 | 1992 | 5 | 0.100 |
Why?
|
Pattern Recognition, Visual | 1 | 1992 | 18 | 0.100 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 90 | 0.100 |
Why?
|
Socioeconomic Factors | 2 | 2010 | 302 | 0.090 |
Why?
|
Blood Platelets | 1 | 2011 | 39 | 0.090 |
Why?
|
Caudate Nucleus | 1 | 2011 | 11 | 0.090 |
Why?
|
Reading | 1 | 2011 | 38 | 0.090 |
Why?
|
Bethanechol Compounds | 2 | 1988 | 5 | 0.090 |
Why?
|
Putamen | 1 | 2011 | 19 | 0.090 |
Why?
|
Surveys and Questionnaires | 4 | 2019 | 1144 | 0.090 |
Why?
|
Genome-Wide Association Study | 1 | 2012 | 280 | 0.090 |
Why?
|
Psychomotor Disorders | 1 | 2010 | 11 | 0.090 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2011 | 102 | 0.090 |
Why?
|
Stroop Test | 1 | 2010 | 3 | 0.090 |
Why?
|
Stroke | 1 | 2013 | 261 | 0.090 |
Why?
|
Data Interpretation, Statistical | 1 | 2010 | 77 | 0.080 |
Why?
|
Games, Experimental | 1 | 2009 | 7 | 0.080 |
Why?
|
Atrophy | 3 | 2016 | 91 | 0.080 |
Why?
|
Social Values | 1 | 2008 | 10 | 0.080 |
Why?
|
Antipsychotic Agents | 2 | 2002 | 55 | 0.080 |
Why?
|
Frontal Lobe | 2 | 1995 | 81 | 0.080 |
Why?
|
Multivariate Analysis | 3 | 2015 | 329 | 0.080 |
Why?
|
Dementia | 1 | 2014 | 560 | 0.080 |
Why?
|
Reproducibility of Results | 4 | 2012 | 676 | 0.080 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 5 | 1996 | 79 | 0.070 |
Why?
|
Gray Matter | 2 | 2020 | 50 | 0.070 |
Why?
|
HIV | 2 | 2011 | 39 | 0.070 |
Why?
|
Infusion Pumps | 1 | 1988 | 6 | 0.070 |
Why?
|
Alzheimer Disease | 4 | 1992 | 2109 | 0.070 |
Why?
|
Societies, Medical | 1 | 2008 | 121 | 0.070 |
Why?
|
Leadership | 1 | 2008 | 92 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2008 | 132 | 0.070 |
Why?
|
Confidence Intervals | 1 | 2007 | 94 | 0.070 |
Why?
|
Retrospective Studies | 3 | 2017 | 3538 | 0.070 |
Why?
|
Bisexuality | 2 | 2017 | 7 | 0.070 |
Why?
|
Mental Health | 2 | 2019 | 108 | 0.060 |
Why?
|
Depressive Disorder, Major | 2 | 2003 | 100 | 0.060 |
Why?
|
Research | 1 | 2005 | 39 | 0.060 |
Why?
|
Intracranial Arteriovenous Malformations | 2 | 1995 | 10 | 0.060 |
Why?
|
Homosexuality | 2 | 2015 | 6 | 0.060 |
Why?
|
Substance Abuse Detection | 1 | 2004 | 5 | 0.060 |
Why?
|
Activities of Daily Living | 3 | 2002 | 595 | 0.060 |
Why?
|
Alleles | 2 | 2014 | 216 | 0.060 |
Why?
|
Alcohol Drinking | 1 | 2004 | 75 | 0.060 |
Why?
|
Organ Size | 2 | 2016 | 95 | 0.050 |
Why?
|
Gene Expression | 2 | 2014 | 199 | 0.050 |
Why?
|
Probability | 1 | 2004 | 88 | 0.050 |
Why?
|
Electroconvulsive Therapy | 1 | 2003 | 16 | 0.050 |
Why?
|
Electric Stimulation | 1 | 2003 | 51 | 0.050 |
Why?
|
Principal Component Analysis | 2 | 2013 | 23 | 0.050 |
Why?
|
Schizotypal Personality Disorder | 1 | 1982 | 2 | 0.050 |
Why?
|
Interferon-alpha | 1 | 2002 | 26 | 0.050 |
Why?
|
Rehabilitation, Vocational | 1 | 2002 | 2 | 0.050 |
Why?
|
Delusions | 1 | 2002 | 9 | 0.050 |
Why?
|
Immunoglobulin G | 1 | 2002 | 80 | 0.050 |
Why?
|
Hallucinations | 1 | 2002 | 42 | 0.050 |
Why?
|
Communication | 1 | 1982 | 104 | 0.050 |
Why?
|
Reference Values | 4 | 2012 | 186 | 0.050 |
Why?
|
Patient Discharge | 1 | 2002 | 158 | 0.050 |
Why?
|
Chronic Disease | 1 | 2002 | 415 | 0.040 |
Why?
|
Cardiovascular Diseases | 2 | 2016 | 321 | 0.040 |
Why?
|
Zalcitabine | 1 | 1999 | 1 | 0.040 |
Why?
|
Didanosine | 1 | 1999 | 3 | 0.040 |
Why?
|
CD4-CD8 Ratio | 1 | 1999 | 4 | 0.040 |
Why?
|
Alkynes | 1 | 2019 | 4 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2019 | 9 | 0.040 |
Why?
|
Waist Circumference | 1 | 2019 | 35 | 0.040 |
Why?
|
Cities | 1 | 2018 | 15 | 0.040 |
Why?
|
Movement | 1 | 2019 | 112 | 0.040 |
Why?
|
Posture | 1 | 1998 | 63 | 0.040 |
Why?
|
Parietal Lobe | 2 | 1995 | 16 | 0.040 |
Why?
|
Postoperative Complications | 2 | 1995 | 916 | 0.040 |
Why?
|
Pilot Projects | 1 | 1999 | 420 | 0.040 |
Why?
|
Dominance, Cerebral | 2 | 1995 | 15 | 0.040 |
Why?
|
Cell Count | 1 | 2017 | 81 | 0.040 |
Why?
|
Radiography | 2 | 2011 | 619 | 0.040 |
Why?
|
CD4 Antigens | 1 | 2017 | 29 | 0.040 |
Why?
|
Tobacco Smoking | 1 | 2017 | 5 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2017 | 47 | 0.030 |
Why?
|
Systems Biology | 1 | 2017 | 6 | 0.030 |
Why?
|
Mental Status and Dementia Tests | 1 | 2017 | 56 | 0.030 |
Why?
|
Gene Regulatory Networks | 1 | 2017 | 29 | 0.030 |
Why?
|
Dopamine | 2 | 2014 | 82 | 0.030 |
Why?
|
Medication Adherence | 1 | 2017 | 49 | 0.030 |
Why?
|
Body Mass Index | 1 | 2019 | 458 | 0.030 |
Why?
|
Cerebrovascular Circulation | 2 | 1995 | 34 | 0.030 |
Why?
|
Hypercholesterolemia | 1 | 2015 | 24 | 0.030 |
Why?
|
Language | 1 | 1996 | 63 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2017 | 520 | 0.030 |
Why?
|
Language Disorders | 1 | 1995 | 7 | 0.030 |
Why?
|
Leptin | 1 | 2015 | 21 | 0.030 |
Why?
|
Serotyping | 1 | 2014 | 8 | 0.030 |
Why?
|
Methylphenidate | 1 | 1995 | 8 | 0.030 |
Why?
|
Hematoma | 1 | 1995 | 19 | 0.030 |
Why?
|
Anomia | 1 | 1994 | 1 | 0.030 |
Why?
|
Aphasia, Broca | 1 | 1994 | 2 | 0.030 |
Why?
|
Temporal Lobe | 1 | 1995 | 83 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2015 | 96 | 0.030 |
Why?
|
Models, Statistical | 1 | 2015 | 127 | 0.030 |
Why?
|
Smoking Prevention | 2 | 1986 | 17 | 0.030 |
Why?
|
Chemokine CCL3 | 1 | 2014 | 8 | 0.030 |
Why?
|
Adipose Tissue | 1 | 2015 | 76 | 0.030 |
Why?
|
Motivation | 1 | 1995 | 85 | 0.030 |
Why?
|
Survival Analysis | 1 | 2014 | 257 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2014 | 21 | 0.030 |
Why?
|
Models, Neurological | 1 | 1994 | 25 | 0.030 |
Why?
|
Cerebral Infarction | 1 | 1995 | 147 | 0.030 |
Why?
|
Heroin | 1 | 2013 | 2 | 0.030 |
Why?
|
Avoidance Learning | 2 | 2010 | 6 | 0.030 |
Why?
|
Color Perception | 1 | 1992 | 5 | 0.030 |
Why?
|
Cannabis | 1 | 2012 | 11 | 0.020 |
Why?
|
Quality Control | 1 | 2012 | 27 | 0.020 |
Why?
|
Models, Genetic | 1 | 2012 | 41 | 0.020 |
Why?
|
Haplotypes | 1 | 2012 | 58 | 0.020 |
Why?
|
Biomarkers | 1 | 2015 | 562 | 0.020 |
Why?
|
Platelet Count | 1 | 2011 | 16 | 0.020 |
Why?
|
Animals | 2 | 2018 | 3642 | 0.020 |
Why?
|
Bethanechol | 2 | 1988 | 4 | 0.020 |
Why?
|
Health Surveys | 1 | 2011 | 86 | 0.020 |
Why?
|
Phenotype | 1 | 2012 | 312 | 0.020 |
Why?
|
Diagnosis, Dual (Psychiatry) | 1 | 2010 | 5 | 0.020 |
Why?
|
Neuroimaging | 1 | 2011 | 126 | 0.020 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2011 | 64 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2010 | 43 | 0.020 |
Why?
|
Task Performance and Analysis | 1 | 2010 | 47 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 347 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2011 | 164 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2012 | 381 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2011 | 195 | 0.020 |
Why?
|
Verbal Behavior | 2 | 1994 | 16 | 0.020 |
Why?
|
Ultrasonography | 1 | 2011 | 227 | 0.020 |
Why?
|
Prognosis | 1 | 2011 | 785 | 0.020 |
Why?
|
Algorithms | 1 | 2011 | 350 | 0.020 |
Why?
|
Behavior | 1 | 1988 | 25 | 0.020 |
Why?
|
Anisotropy | 1 | 2008 | 44 | 0.020 |
Why?
|
Mental Status Schedule | 1 | 1988 | 90 | 0.020 |
Why?
|
Affect | 1 | 2008 | 60 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1988 | 333 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2007 | 89 | 0.020 |
Why?
|
Mental Processes | 1 | 2006 | 17 | 0.020 |
Why?
|
Reference Standards | 1 | 2006 | 23 | 0.020 |
Why?
|
Biopsy | 1 | 1987 | 201 | 0.020 |
Why?
|
Counseling | 1 | 1986 | 42 | 0.020 |
Why?
|
Intelligence | 1 | 2005 | 18 | 0.020 |
Why?
|
Parkinson Disease | 1 | 1992 | 670 | 0.010 |
Why?
|
Regional Blood Flow | 2 | 1995 | 8 | 0.010 |
Why?
|
Behavior Therapy | 1 | 1986 | 86 | 0.010 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2003 | 17 | 0.010 |
Why?
|
Aversive Therapy | 1 | 1983 | 1 | 0.010 |
Why?
|
Hypophysectomy | 1 | 1983 | 3 | 0.010 |
Why?
|
Schizophrenic Language | 1 | 1982 | 1 | 0.010 |
Why?
|
Morphine | 1 | 1983 | 72 | 0.010 |
Why?
|
Motor Activity | 1 | 2003 | 323 | 0.010 |
Why?
|
Reflex | 1 | 1998 | 2 | 0.010 |
Why?
|
Electromyography | 1 | 1998 | 71 | 0.010 |
Why?
|
Leg | 1 | 1998 | 50 | 0.010 |
Why?
|
Forecasting | 1 | 1998 | 91 | 0.010 |
Why?
|
Rotation | 1 | 1998 | 137 | 0.010 |
Why?
|
Epilepsy | 1 | 1996 | 60 | 0.010 |
Why?
|
Amobarbital | 1 | 1995 | 1 | 0.010 |
Why?
|
Bolivia | 1 | 1995 | 3 | 0.010 |
Why?
|
Epilepsy, Generalized | 1 | 1995 | 2 | 0.010 |
Why?
|
Arteriovenous Malformations | 1 | 1995 | 3 | 0.010 |
Why?
|
Social Behavior | 1 | 1995 | 67 | 0.010 |
Why?
|
Dopamine D2 Receptor Antagonists | 1 | 1994 | 1 | 0.010 |
Why?
|
Receptors, Dopamine D2 | 1 | 1994 | 12 | 0.010 |
Why?
|
Neural Pathways | 1 | 1994 | 63 | 0.010 |
Why?
|
Postoperative Period | 1 | 1995 | 333 | 0.010 |
Why?
|
Cerebral Ventricles | 1 | 1988 | 17 | 0.000 |
Why?
|
Double-Blind Method | 1 | 1988 | 406 | 0.000 |
Why?
|
Clinical Trials as Topic | 1 | 1988 | 216 | 0.000 |
Why?
|
Treatment Outcome | 1 | 1995 | 3485 | 0.000 |
Why?
|
Drug Tolerance | 1 | 1983 | 6 | 0.000 |
Why?
|
Conditioning, Classical | 1 | 1983 | 4 | 0.000 |
Why?
|
Rats | 1 | 1983 | 664 | 0.000 |
Why?
|